| PubMed |
Abstract |
RScore(About this table) |
| 18243711 |
Song KS, Lee SH, Chun HJ, Kim JY, Jung ME, Ahn K, Kim SU, Kim J, Lee J: Design, synthesis and biological evaluation of piperazine analogues as CB1 cannabinoid receptor ligands. Bioorg Med Chem. 2008 Apr 1;16(7):4035-51. Epub 2008 Jan 19.
|
35(0,1,1,5) |
Details |
| 20099888 |
Long JZ, Jin X, Adibekian A, Li W, Cravatt BF: Characterization of tunable piperidine and piperazine carbamates as inhibitors of endocannabinoid hydrolases. J Med Chem. 2010 Feb 25;53(4):1830-42.
Piperidine/piperazine carbamates show excellent in vivo activity, raising brain endocannabinoid levels and producing CB1-dependent behavioral effects in mice, suggesting that they represent a promising class of inhibitors for studying the endogenous functions of MAGL and FAAH. |
31(0,1,1,1) |
Details |
| 19428788 |
Sperlagh B, Windisch K, Ando RD, Sylvester Vizi E: Neurochemical evidence that stimulation of CB1 cannabinoid receptors on GABAergic nerve terminals activates the dopaminergic reward system by increasing dopamine release in the rat nucleus accumbens. Neurochem Int. 2009 Jun;54(7):452-7. Epub 2009 Feb 6.
The cannabinoid agonist (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl) pyrrolo [1,2,3-de]-1,4 -benzoxazin-6-yl]-1-naphthalenylmethanone mesylate (WIN55,212-2, 100 nM) significantly enhanced stimulation-evoked [(3) H] dopamine release in the presence of the selective dopamine transporter inhibitor 1-[2-[bis-(4-fluorophenyl) methoxy] ethyl]-4-(3-phenylpropyl) piperazine dihydrochloride (GBR12909, 100 nM). |
3(0,0,0,3) |
Details |